Gregory Connelly, PhD

Vertex Pharmaceuticals
Senior Director - Continuous Manufacturing
Gregory Connelly, PhD, is a Director of Continuous Manufacturing at Vertex Pharmaceuticals in Boston, where he has been a key driver of the Vertex CM program since its inception. He has guided the development of several Vertex products that are filed and approved as fully continuous processes. His team works to increase fundamental understanding of the various unit operations that comprise Vertex’s CM platform, and they manage all design and qualification of system process equipment and control software. Greg holds a BS in physics and mathematics from Loyola University and a PhD in bio-physics from the University of Pennsylvania. Greg is a member of the Working Groups for Continuous Manufacturing in both ISPE and the IQ Consortium, and he is the Vice Chair of the Drug Product Leadership Group within IQ. Greg’s 20-year career in the pharmaceutical industry has spanned from early-stage research to commercial product development. He has been an ISPE member since 2020.

Related Articles

Good Practice Guide: Continuous Manufacturing of Oral Solid Dosage Forms
iSpeak Blog
Should Your Company Switch to Continuous Manufacturing?

As the benefits of continuous manufacturing became more apparent in the pharmaceutical industry, companies looked for ways to incorporate the technology into their manufacturing processes. In 2017 The ISPE Oral Solid Dosage (OSD) Community of Practice (CoP) formed a working team to advance the use of continuous manufacturing in the pharmaceutical industry and to increase the long-term...

Continuous Manufacturing Good Practice Guide Is Planned
Features
Continuous Manufacturing Good Practice Guide Is Planned

The ISPE OSD Community of Practice Continuous Manufacturing Subcommittee is planning a Good Practice Guide to capture information developed over several years by the team to establish equipment requirements, identify opportunities for harmonization and flexible integration, and suggest where current equipment may be enhanced to work with continuous manufacturing platforms of the future.